The MRC Confidence in Concepts at UCL Fund 2014

Lead Research Organisation: University College London

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50

publication icon
Day AGE (2017) The Effect of Hypothermic and Cryogenic Preservation on Engineered Neural Tissue. in Tissue engineering. Part C, Methods

 
Description A Chemical Imaging Platform for Discovery Biosciences (CIP-DB).
Amount £353,040 (GBP)
Funding ID BB/R013667/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 05/2018 
End 04/2019
 
Description AMR, Dagan Jenkins
Amount £160,610 (GBP)
Organisation Action Medical Research 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2016 
End 12/2017
 
Description Action Medical Research Project Grant, Greene
Amount £177,915 (GBP)
Funding ID GN2403 
Organisation Action Medical Research 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2016 
End 12/2017
 
Description Daphne Jackson Memorial Trust Fellowship, Greene
Amount £49,908 (GBP)
Organisation University of Surrey 
Department Daphne Jackson Trust
Sector Charity/Non Profit
Country United Kingdom
Start 05/2017 
End 12/2018
 
Description GOSH BRC, Dagan Jenkins
Amount £49,878 (GBP)
Organisation Great Ormond Street Hospital (GOSH) 
Sector Hospitals
Country United Kingdom
Start 09/2016 
End 08/2017
 
Description Gene therapy for Non-Ketotic Hyperglycinemia
Amount £373,597 (GBP)
Organisation LifeArc 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2019 
End 09/2022
 
Description Investment Accelerator Pilot - Phillips
Amount £150,000 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start  
 
Description Joseph's Goal NKH Charity, Greene
Amount £160,000 (GBP)
Organisation NKH Charity 
Sector Charity/Non Profit
Country United States
Start 09/2016 
End 12/2017
 
Description MRC DPFS, McGregor
Amount £1,094,729 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 03/2018 
End 02/2021
 
Description Mathematical Modelling Led Design of Tissue-Engineered Constructs: A New Paradigm for Peripheral Nerve Repair (NerveDesign)
Amount £1,080,646 (GBP)
Funding ID EP/R004463/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 01/2018 
End 12/2022
 
Description PoC fund - Waddington
Amount £13,995 (GBP)
Organisation UCL Business 
Sector Private
Country United Kingdom
Start  
 
Description Therapeutic targeting of LRG1 in tumour angiogenesis - John Greenwood
Amount £1,100,000 (GBP)
Organisation University College London 
Department Technology Fund
Sector Academic/University
Country United Kingdom
Start 09/2019 
End 09/2020
 
Description Tissue-derived ECM hydrogels for peripheral nerve repair
Amount £75,000 (GBP)
Funding ID 1786197 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 09/2016 
End 09/2020
 
Description UCL TAS fund, Waddington
Amount £72,866 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 01/2018 
End 12/2018
 
Description UCL Technology Fund, Philips
Amount £100,000 (GBP)
Organisation University College London 
Sector Academic/University
Country United Kingdom
Start 01/2017 
End 12/2017
 
Description UCLB Tech Fund, Greenwood
Amount £100,000 (GBP)
Organisation University College London 
Sector Academic/University
Country United Kingdom
Start 09/2017 
End 09/2018
 
Description WT Innovator - Nick Greene
Amount £365,837 (GBP)
Funding ID 210774/Z/18/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description WT Investigator Award, John Greenwood
Amount £1,714,270 (GBP)
Funding ID 206413/Z/17/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2017 
End 05/2022
 
Title BIOPROSTHETIC HEART VALVE 
Description A bioprosthetic heart valve and the method for fabricating said bioprosthetic heart valve; the method comprising: providing: a sheet of biological tissue (11); a sheet of a biocompatible material (2), and a stent (4), the stent (4) having an upstream edge (41) and a downstream edge (42) as well as an inner surface and an outer surface; attaching the biological tissue (11) to the biocompatible material (2) along a suture line (3); folding the biocompatible material to form a tubular structure with the attached biological tissue located on the inner surface of the tubular structure, the biological tissue forming the leaflets (11) of the heart valve; securing the stent around the outer surface of the tubular structure such that the tubular structure extends in an upstream direction beyond the upstream edge of the stent and in a downstream direction beyond the downstream edge of the stent; cutting at least one region of the biocompatible material at the downstream end of the tubular structure; folding the biocompatible material at the cut region away from the biological tissue and around the downstream edge of the stent and securing it to the outer surface of the stent; and folding the biocompatible material at the upstream end of the tubular structure around the upstream edge of the stent and attaching to the outer surface of the stent so that the inner and outer surfaces of the stent are covered with no more than a single layer of the biocompatible material. 
IP Reference WO2018011592 
Protection Patent application published
Year Protection Granted 2018
Licensed No
Impact None as yet
 
Title COMPOSITION COMPRISING VEGF ANTAGONISTS AND A CATIONIC PEPTIDE AND USES THEREOF 
Description The invention relates compositions comprising a small cationic peptide and a VEGF antagonist, and the use of such compositions in the treatment or prevention of conditions characterised by VEGF dysfunction, for example vasculoproliferative conditions, particularly in the eye. 
IP Reference WO2019038552 
Protection Patent application published
Year Protection Granted 2019
Licensed No
Impact still in development
 
Title Intranasal delivery of fluorescent marker 
Description The present invention provides a method of diagnosing a CNS disorder comprising administering a fluorescent marker of retinal integrity to a subject and generating an image of the subject's eye, wherein the fluorescent marker is delivered by intranasal administration is also provided and fluorescent markers of retinal integrity for use in such methods. Also provided is a pharmaceutical composition comprising an annex in or a functional fragment or derivative thereof conjugated to a compound of 2 kDa or less, wherein the composition comprises annex in or a functional fragment or derivative thereof conjugated at a concentration of at least mg/ml. 
IP Reference AU2019259198 
Protection Patent application published
Year Protection Granted 2020
Licensed No
Impact Still in development
 
Title RETROVIRAL VECTORS 
Description There is disclosed a retroviral vector comprising a primer binding site, a long terminal repeat and an RNA packaging sequence, wherein the RNA packaging sequence is located 3' of the long terminal repeat and no long terminal repeat is located 3' of the RNA packaging sequence such that reverse transcription initiated at the primer binding site does not lead to reverse transcription of the RNA packaging sequence into vector DNA in a target cell. Also described is a host cell, a virion, a pharmaceutical composition, a method and uses including or involving the vector described above. Further, a cell or transgenic animal produced by using the vector is also described. 
IP Reference WO2015056014 
Protection Patent application published
Year Protection Granted 2015
Licensed No
Impact too early
 
Title TREATMENT 
Description The invention provides an antibody or fragment thereof that specifically binds to human Lrg1. 
IP Reference US2018028609 
Protection Patent application published
Year Protection Granted 2018
Licensed Yes
Impact Still in development
 
Title TREATMENT 
Description The invention provides an antibody or fragment thereof that specifically binds to human Lrg1. 
IP Reference US2020330591 
Protection Patent application published
Year Protection Granted 2020
Licensed Yes
Impact still in development
 
Title TREATMENT 
Description The invention provides an antibody or fragment thereof that specifically binds to human Lrgl. 
IP Reference CA2977888 
Protection Patent application published
Year Protection Granted 2016
Licensed Yes
Impact still in development
 
Title TREATMENT 
Description The invention provides an antibody or fragment thereof that specifically binds to human Lrgl. 
IP Reference WO2016135462 
Protection Patent application published
Year Protection Granted 2016
Licensed Yes
Impact still in development
 
Title TREATMENT OF CANCER 
Description This invention relates to the field of molecular physiology. Specifically, this invention relates to the prevention and/or treatment of cancer. Leucine-rich alpha-2-glycoprotein (Lrg1) has been demonstrated to be expressed in a range of cancer cells. Antagonists of Lrg1 can be used to prevent and/or treat cancer by an effect on neoplastic cells. 
IP Reference US2015132226 
Protection Patent application published
Year Protection Granted 2015
Licensed No
Impact none as yet
 
Title USE OF ANTIBODIES AND ANTAGONISTS DIRECTED AGAINST LRG1 IN TREATMENT 
Description Antibody directed to LRG1 
IP Reference EP3262069 
Protection Patent application published
Year Protection Granted 2018
Licensed Yes
Impact still in development